News

Designed to slow down tumor growth, the FPA144 prevents the binding of fibroblast growth factors to FGF receptor 2b (FGFR2b) and is being developed initially as a monotherapy

Under the deal, Pfizer will review medicines that are currently under development to find substances with a probable or high risk of abuse in sport. The company will

Reassuring Member States over safety of flu vaccine, the review conducted by the committee found that the vaccine was safe for administration in vaccination campaigns. The review follows

A novel screening approach has been developed by Monash University researchers, led by Professor David Jans in the Department of Biochemistry, to identify new classes of antiviral drugs.

In an emailed statement, a GSK spokesman was quoted by Reuters as saying: "This is a significant programme and will result in the loss of several hundred employees

This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes

The multi-year grants that worth about $3.5m will be used for the projects that focus on hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in high-risk

The collaboration will focus on the delivery of muscle-protein fusions, and treatment of multiple indications, in the fields of muscular dystrophies, glycogen storage diseases, myopathies and enzyme-deficiency disorders.

The identity of the pharmaceutical company and its target therapy, which is approved in the U.S and Europe for the treatment of a high prevalence disease of the